Its potential molecular mechanism suggests that copper ionophores can kill ccRCC cells (with high expression of FDX1), which may become a new direction of tumor therapy with important clinical guiding significance. The gene discussed is FDX1; the disease is nonpapillary renal cell carcinoma.